• Product NameKD025 (SLx-2119)
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityKD025 is an orally available, and selective ROCK2 inhibitor with IC50 and Ki of 60 nM and 41 nM, respectively. Phase 2.
• Target NameROCK inhibitor
• CAS No. 911417-87-3
• Calculated MW 452.51
• Formulation C26H24N6O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:CC(C)NC(=O)COC1=CC(=CC=C1)C1=NC2=CC=CC=C2C(NC2=CC3=C(NN=C3)C=C2)=N1 |c:10,12,19,21,31,34,36,t:8,15,17,26,28|
  Pathways:Cell Cycle/Checkpoint; Stem Cells
  Receptor:ROCK2; ROCK2
  Boling pt:
  Melting pt:
  Solubility:Ethanol: <1 mg/mL DMSO: 90 mg/mL (198.89 mM) Water: <1 mg/mL
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Lee JH, et al. Ann Clin Transl Neurol. 2014, 1(1), 2-14.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting